par Steinfeld, Serge 
;Youinou, Pierre
Référence Expert opinion on biological therapy, 6, 9, page (943-949)
Publication Publié, 2006-09
;Youinou, PierreRéférence Expert opinion on biological therapy, 6, 9, page (943-949)
Publication Publié, 2006-09
Article révisé par les pairs
| Résumé : | B cells play an important role in the pathogenesis of many autoimmune diseases. Different approaches targeting the B cell compartment are under investigation. Selective modulation of B cells has been recently achieved using a humanised monoclonal antibody against the B cell surface marker CD22. This antibody (epratuzumab) was originally developed for the treatment of non-Hodgkin's lymphoma and was found to be effective, with a very good safety profile. Recent studies have demonstrated the efficacy and safety of epratuzumab in several autoimmune diseases, including systemic lupus erythematosus and primary Sjögren's syndrome. © 2006 Informa UK Ltd. |
